EXECUTIVE ENGAGEMENTS
OUTREACH
10861
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1303
Interactions with Platform & by Email
PARTICIPANTS
326
Unique # Participated
VALIDATIONS
147
Responses Validated*
COMPETITORS
42
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
108
PAGES
180
EDITION
7
PRICE
USD $4950
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Ulcerative Colitis Therapeutics estimated at US$5.6 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Ulcerative Proctitis, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Proctosigmoiditis segment is readjusted to a revised 5.4% CAGR for the next 7-year period.
The Ulcerative Colitis Therapeutics market in the U.S. is estimated at US$1.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
In the global Left-sided Colitis segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$912.9 Million by the year 2027.
SELECT PLAYERS
Abbott Laboratories, Inc.; AbbVie, Inc.; Amgen, Inc.; Arena Pharmaceuticals, Inc.; Astellas Pharma, Inc.; AstraZeneca PLC; Avaxia Biologics, Inc.; BioLineRx Ltd.; Celgene Corporation; Cosmo Pharmaceuticals NV; EA Pharma Co., Ltd.; Eisai Co., Ltd.; Ferring Pharmaceuticals; Galapagos NV; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline PLC; Hutchison MediPharma Limited; Immune Pharmaceuticals, Inc.; InDex Pharmaceuticals Holding AB; Janssen Biotech, Inc.; Kaken Pharmaceutical Co., Ltd.; Kissei Pharmaceutical Co., Ltd.; Kyowa Hakko Kirin Co., Ltd.; Lipid Therapeutics GmbH; Meda AB; Merck & Co., Inc.; Mitsubishi Tanabe Pharma Corporation; Mochida Pharmaceutical Co., Ltd.; Morphotek, Inc.; Nestle SA; Pfizer, Inc.; Procter & Gamble Company, The; Qu Biologics Inc.; Salix Pharmaceuticals, Inc.; Shield Therapeutics PLC; Shire Pharmaceuticals, Inc.; Sterna Biologicals GmbH & Co. KG; Takeda Pharmaceuticals Company Ltd.; Tillotts Pharma AG; TopiVert Ltd.; UCB SA; Zeria Pharmaceutical Co., Ltd.
SEGMENTS
» Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis) » Route of Administration (Oral, Injectables)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Ulcerative Proctitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Ulcerative Proctitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Ulcerative Proctitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Proctosigmoiditis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Proctosigmoiditis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Proctosigmoiditis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Left-sided Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Left-sided Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Left-sided Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Pancolitis or Universal Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Pancolitis or Universal Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Pancolitis or Universal Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Fulminant Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Fulminant Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Fulminant Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 42 |
China Has Risen Into An Economic Powerhouse.
Find Out How You Can Leverage This Opportunity!
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com